Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer - Concepedia

Concepedia

Publication | Closed Access

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

22

Citations

14

References

2010

Year

J. M. Roca, Vicente Alonso, Carles Pericay, P. Escudero, Antonieta Salud, Ferrán Losa, L Lopez, Imma Guasch, Miguel Méndez, G. Quintero Aldana,

Abstract

The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen.

References

	Year	Citations

Page 1